Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · IEX Real-Time Price · USD
5.33
+0.01 (0.19%)
At close: Jul 19, 2024, 4:00 PM
5.31
-0.02 (-0.38%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Inozyme Pharma Employees
Inozyme Pharma had 59 employees as of December 31, 2023. The number of employees increased by 3 or 5.36% compared to the previous year.
Employees
59
Change (1Y)
3
Growth (1Y)
5.36%
Revenue / Employee
n/a
Profits / Employee
-$1,306,983
Market Cap
329.69M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 59 | 3 | 5.36% |
Dec 31, 2022 | 56 | 6 | 12.00% |
Dec 31, 2021 | 50 | 12 | 31.58% |
Dec 31, 2020 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
ModivCare | 21,200 |
Nevro | 1,215 |
Spok Holdings | 384 |
Kamada | 378 |
ADC Therapeutics | 274 |
Nautilus Biotechnology | 167 |
Foghorn Therapeutics | 116 |
Cabaletta Bio | 103 |
INZY News
- 20 days ago - Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency - GlobeNewsWire
- 4 weeks ago - Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH) - GlobeNewsWire
- 2 months ago - Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences - GlobeNewsWire
- 2 months ago - Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference - GlobeNewsWire
- 2 months ago - Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency - GlobeNewsWire
- 3 months ago - Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire